Presidio Property Trust, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Rental income | $16.5M-11.1% | $18.5M+6.5% | $17.4M+1.1% | $17.2M-6.6% | $18.4M |
| Fees and other income | $344K-14.4% | $401K+65.1% | $243K-56.6% | $561K-30.8% | $811K |
| Total revenue | $16.8M-11.2% | $18.9M+7.3% | $17.6M-0.7% | $17.8M-7.6% | $19.2M |
| Rental operating costs | $6.2M-1.6% | $6.3M+4.9% | $6.0M+2.1% | $5.8M-5.5% | $6.2M |
| General and administrative | $5.7M-24.2% | $7.5M+10.8% | $6.8M+10.2% | $6.2M-1.0% | $6.2M |
| Depreciation and amortization | $4.9M-11.8% | $5.5M+1.7% | $5.4M-0.7% | $5.5M+1.3% | $5.4M |
| Asset Impairment Charges | $6.4M+227.2% | $2.0M-39.4% | $3.2M | $0 | — |
| Total costs and expenses | $23.2M+8.9% | $21.3M-0.7% | $21.4M+22.6% | $17.5M-5.1% | $18.4M |
| Interest and other income, net | $21K+113.8% | -$151K-110.5% | $1.4M+6710.4% | $21K+149.2% | -$43K |
| Gain on sales of real estate, net | $5.4M+58.9% | $3.4M+5.8% | $3.2M-36.2% | $5.1M+104.2% | $2.5M |
| Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9) | -$188K+98.9% | -$17.9M+23.3% | -$23.4M-1257.1% | $2.0M | — |
| Income tax (expense) benefit | -$463K-661.1% | -$61K-118.1% | $336K+127.6% | -$1.2M-2653.3% | $48K |
| Total loss, net | -$1.2M+94.0% | -$20.8M-222.4% | $17.0M+1324.1% | $1.2M+152.2% | -$2.3M |
| Net loss: | -$7.6M+67.1% | -$23.1M-275.3% | $13.2M+787.1% | $1.5M+201.5% | -$1.5M |
| Less: Income attributable to noncontrolling interests | -$686K+72.8% | -$2.5M+16.7% | -$3.0M+16.1% | -$3.6M-67.1% | -$2.2M |
| Net loss attributable to Presidio Property Trust, Inc. stockholders | -$8.3M+67.7% | -$25.6M-352.6% | $10.1M+577.0% | -$2.1M+41.3% | -$3.6M |
| Less: Preferred Stock Series D dividends | -$2.3M-2.6% | -$2.2M-5.6% | -$2.1M+1.6% | -$2.2M-83.4% | -$1.2M |
| Net loss attributable to Presidio Property Trust, Inc. common stockholders | -$10.6M+62.1% | -$27.9M-447.1% | $8.0M+219.2% | -$6.7M-40.4% | -$4.8M |
| Basic & Diluted (in dollars per share) | -$8.65+61.6% | -$22.50-3408.8% | $0.68+219.3% | -$0.57-23.9% | -$0.46 |
| Weighted average number of common shares outstanding - basic & dilutive (in shares) | 1.2M-1.4% | 1.2M-89.5% | 11.8M+0.8% | 11.8M+13.7% | 10.3M |
| Mortgage Notes [Member] | |||||
| Interest expense - mortgage notes | -$6.1M-0.0% | -$6.1M-20.9% | -$5.0M-6.2% | -$4.7M-3.7% | -$4.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.